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Abstract
 .HIV-regulated expression of the diphtheria toxin A fragment gene HIV-DT-A is a potential gene therapy approach to
AIDS. Since cationic liposomes are safe and non-immunogenic for in vivo gene delivery, we examined whether
 .LipofectAMINE or DMRIE reagent could mediate the transfection of HIV-DT-A pTHA43 or the HIV-regulated luciferase
 . 3gene pLUCA43 into HIV-infected or uninfected HeLa cells. pLUCA43 was expressed at a 10 -fold higher level in
HeLarLAV cells than in uninfected HeLa cells, while the extent of expression of RSV-regulated luciferase was the same in
both cell lines. Co-transfection of HeLa cells with pTHA43 and the proviral HIV clone, HXBDBgl, resulted in complete
inhibition of virus production. In contrast, the delivery of HIV-DT-A to chronically infected HeLarLAV or HeLarIIIB
cells, or to HeLa CD4q cells before infection, did not have a specific effect on virus production, since treatment of cells
with control plasmids also reduced virus production. This reduction could be ascribed to cytotoxicity of the reagents. The
efficiency of transfection, as measured by the percentage of cells expressing b-gal, was ;5%. Thus, cationic liposome-
mediated transfection was too inefficient to inhibit virus production when the DT-A was delivered by cationic liposomes to
chronically- or de novo- infected cells. However, when both the virus and DT-A genes were delivered into the same cells by
cationic liposomes, DT-A was very effective at inhibiting virus production. Our results indicate that the successful use of
cationic liposomes for gene therapy will require the improvement of their transfection efficiency.
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1. Introduction
The genetic approach to HIV infection is based on
the notion that transfer of therapeutic genes into
target cells will render them resistant to HIV replica-
tion. HIV gene therapy strategies have been based on
RNA-targeted antivirals antisense DNA and RNA,
.ribozymes, RNA decoys , intracellular proteins that
compete or interfere with viral functions, and in-
ducible toxins that kill host cells subsequent to infec-
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tion by the virus. In each case, the therapeutic benefit
will be determined by the antiviral gene chosen,
intracellular expression and stability, delivery system,
target cells and tissues, and localization of the gene
w xproduct 1 .
Expression of a gene encoding the diphtheria toxin
 .A fragment DT-A , controlled by tissue-specific reg-
ulatory elements, has been used previously to kill
w xselected cell populations 2,3 . DT is composed of
 .two chains: the B chain 342 amino acids , which
mediates adsorption of the toxin to the cell surface,
and the enzymatically active A chain 193 amino
.acids , which is a lethal inhibitor of protein synthesis
when expressed in eukaryotic cells. The B chain is
required for the endocytotic uptake and translocation
into the cytoplasm of the active A chain, which
 .inactivates elongation factor 2 EF-2 required for
translocation of polypeptidyl-tRNA from the acceptor
to the donor site on the eukaryotic ribosome. The
inactivation involves transfer of the ADP-ribosyl
group of NAD to a specific site on EF-2. Binding to
the cytosolic NAD protects DT-A against proteolysis
and permits its activity for long periods within cells.
EF-2 is the only protein ADP-ribosylated by DT-A,
and this specificity depends on the presence in EF-2
of a unique modified histidine residue, diphtamide
w x4 .
Due to the potent toxicity of DT-A, HIV-regulated
expression of the DT-A gene can be an effective
strategy to eliminate HIV-infected cells. The DT-A
coding sequence has been linked to cis-acting control
elements unique to HIV, resulting in DT-A gene
expression that is highly dependent on trans-activa-
tion by the HIV regulatory proteins Tat and Rev
w x5–7 . Tat and Rev are expressed early in HIV-in-
fected cells, upregulate the expression of HIV, and
are essential for efficient viral replication. Harrison et
w xal. 5,6 proposed that expression of a lethal DT-A
gene responsive to Tat and Rev should allow for
selective killing of HIV-infected cells.
Previous studies have shown that stable expression
of the HIV-regulated gene for diphtheria toxin A
 .fragment HIV-DT-A , after transfection by electro-
poration or by retroviruses, confers resistance against
w xHIV infection 6–9 . Selected HeLa cell clones con-
taining HIV-DT-A sequences were transfected by
electroporation with an HIV proviral clone,
HXBDBgl, and tested for HIV production. These
clones produce less HIV, by p24 assay, than either
parental HeLa cells or cells expressing an HIV-DT-A
w xframeshift mutant 6 . Similarly, selected H9 cell
clones expressing the HIV-DT-A gene produce less
p24 antigen when transfected with an HIV proviral
clone or infected with laboratory or clinical HIV-1
w xstrains 7,8 . Significant protection against HIV, de-
pendent both on the stock of HIV-1 used and on the
dose, was also observed in selected promonocytic
w xU937 cells after transduction with HIV-DT-A 9 .
These results suggest that virus-induced expression of
the DT-A gene caused the death of infected cells.
In the studies described above, the cells stably
expressing HIV-DT-A were subsequently challenged
with HIV, either by transfection with the proviral
clone or by direct infection with the virus. If expres-
sion of the HIV-DT-A gene can specifically destroy
HIV-infected cells, the strategy could also be applica-
ble to cells which are already infected. Since even
one molecule of DT-A may be sufficient to kill a cell,
even transient expression of HIV-DT-A in an already
chronically or de novo HIV-infected cell could cause
the selective suicide of the cell.
Two of the major problems of gene therapy are the
effective delivery of the therapeutic gene into target
cells, and the safety of the vector carrying the gene.
Cationic liposomes provide a simple means of intro-
ducing DNA and other polynucleotides into eukary-
otic cells, a process generally referred to as ‘lipofec-
tion’. Small unilamellar liposomes composed of
cationic lipids and the membrane fusion-promoting
lipid, phosphatidylethanolamine, spontaneously com-
plex with negatively charged polynucleotides. The
mechanism of interaction between cationic liposomes
and DNA is poorly understood. Several models of the
liposome-DNA complexes, situating the DNA either
outside or inside the liposome, have been proposed
w x10 . Recently, electron microscopy has been used to
study the relationship between the structure of the
liposome-DNA complex and its transfection effi-
w xciency 11–14 . The morphology of the complexes
was found to be dependent on incubation time and
w xthe lipid:DNA ratio. Interestingly, Zabner et al. 14
have reported that even under optimal conditions for
transfection, DMRIE-DNA complexes constitute a
very heterogeneous population.
Plasmid-liposome complexes have several advan-
 .tages as gene transfer vectors: i they can be used to
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transfer expression cassettes of essentially unlimited
 .size; ii they cannot replicate or recombine to form
 .an infectious agent, iii they are non-infectious and
 .appear to be non-immunogenic in vivo and iv they
are simple to manufacture and use, and therefore
w xcost-effective 15–17 . Cationic liposomes have been
w xutilized for gene delivery in vivo 18–22 , and a
direct gene transfer protocol using a liposome-DNA
complex has been approved for injection into solid
w xtumors in patients 23 . Several clinical trials utilizing
liposome-mediated transfection are in progress. Thus,
it will be of interest to establish conditions under
which cationic liposomes can be used for eventual in
vivo transfection of genes with therapeutic activity
against HIV. Our approach contrasts with ex vivo
gene therapy where transfected cells can be selected
in the laboratory before injection into patients.
As a first step toward the utilization of cationic
liposomes for HIV gene therapy in vivo we investi-
 .gated i whether cationic liposomes could be used to
express HIV-regulated luciferase and DT-A genes in
 .HeLa cells, ii whether transient expression of the
DT-A gene could reduce virus production in chroni-
cally infected HeLarLAV and HeLarIIIB cells and
 .iii whether this expression could protect HeLa
CD4q cells against de novo HIV infection. Our
results are the first demonstration that HIV-regulated
luciferase could be expressed in chronically HIV-in-
fected cells and that co-transfection of HIV-DT-A
with an HIV proviral clone could prevent virus pro-
duction. Some of our results have been presented
w xearlier in preliminary form 24 .
2. Materials and methods
2.1. Materials
TM w xLipofectAMINE reagent 25 containing the
w polycationic lipid 2,3-dioleyloxy-N- 2- spermine-
. xcarboxamido ethyl -N,N-dimethyl-1-propanaminium
 .trifluoroacetate DOSPA and the neutral lipid, di-
 .  .oleoylphosphatidylethanolamine DOPE 3:1, wrw ,
w xand Lipofectin Reagent 15 containing the monoca-
w  . xtionic lipid N- 1- 2,3 dioleyloxy -propyl -N,N,N-tri-
 .methylammonium chloride DOTMA and DOPE
 .1:1, wrw were obtained from Gibco BRL Life
 .Technologies Gaithersburg, MD . DMRIE reagent
w x   .26,27 a 1:1 wrw mixture of 1,2-dimyristyl-
oxypropyl-3-dimethyl-hydroxyethylammonium bro-
 . .mide DMRIE and DOPE was synthesized by VI-
 .CAL San Diego, CA . Alamar Blue dye was pur-
chased from Alamar Biosciences Inc. Sacramento,
.CA . The penicillin, streptomycin and L-glutamine
solutions were obtained from Irvine Scientific Santa
.Ana, CA . The b-Gal Staining Kit was obtained from
 .Invitrogen Corporation San Diego, CA .
2.2. Cells and ˝irus
HeLa cells were obtained from the American Type
Culture Collection. HeLarLAV and HeLa CD4q
were obtained through the AIDS Research and Refer-
ence Reagent Program Division of AIDS, NIAID,
.NIH, Bethesda, MD from Drs. Joerg Berg and
w x w xMatthias Wable 28 and Dr. Richard Axel 29 ,
respectively. HeLa and HeLarLAV cells were main-
tained at 378C, under 5% CO in DME-HG medium2
 .  .Irvine Scientific supplemented with 10% vrv FBS
 .  .Sigma; St. Louis, MO , penicillin 100 Urml ,
 .  .streptomycin 100 mgrml and L-glutamine 4 mM .
HeLa CD4q cells were grown in RPMI 1640 medium
 .with 10% FBS, penicillin 100 Urml , streptomycin
 .  .100 mgrml , L-glutamine 2 mM and 0.6 mgrml
 .  .Geneticin G418 sulfate Gibco . The cells were
passaged 1:20 once a week. FACS analysis indicated
that over 90% of the cells were CD4-positive.
The supernatant of chronically infected
H9rHTLV-IIIB cells was used as a source of the
HIV-1 strain, HIV-1 . The culture supernatantsIIIB
were harvested at times of peak p24 production and
stored at y808C. The p24 concentration of the stock
w xwas 1.4 mgrml as determined by ELISA 30 . The
 .tissue culture infectious dose, 50% endpoint TCID ,50
was determined as described by Johnson and Bying-
w xton 31 . The infectious titer per 1 mg p24 was
7.1=103 TCID .50
The presence of cell surface CD4 was examined
by direct immunofluorescence assay, using fluores-
 .cein isothiocyanate FITC -conjugated Leu3 antibody
 .Becton-Dickinson , with FITC-conjugated mouse
IgG as a control. The fluorescence distribution was
analyzed with a fluorescence-activated cell sorter
 .FACScan; Becton-Dickinson, Mountain View, CA .
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2.3. Plasmids
The plasmids used for transient transfection as-
says, pTHA43 containing TatqRev-regulated diph-
. theria toxin A gene; HIV-DT-A , pTHA44 a DT-A
. frameshift mutant of pTHA43 and pLUCA43 con-
taining the HIV LTR and en˝ sequences including
HIV cis-acting repressive sequences and the Rev
 . Xresponsive element RRE in the 3 untranslated re-
. w xgion have been described previously 5 . The plas-
mid pRSVLUC encodes the luciferase reporter gene
under control of the Rous sarcoma virus promoter
w x32 . The HIV proviral clone, HXBDBgl, kindly
provided by Dr. E. Terwilliger, was derived from
w xHXB2 33 by deletion of 500 base pairs between two
w xBg1 II sites in the en˝ region 6,7 . The plasmid
pCMV.SPORT-bgal containing the E. coli gene en-
 .coding b-galactosidase b-gal under control of the
 .cytomegalovirus CMV promoter was obtained from
GIBCO.
2.4. Transfection of cells
HeLa and HeLarLAV cells were seeded at 2=105
cellsrwell in 2 ml of DME-HG medium in 24-well
plates the day before transfection. Cells were ;60-
70% confluent at the time of transfection. Lipo-
TM  .fectAMINE reagent LFA was provided at 0.5
 .mM corresponding to 2 mgrml and DMRIErDOPE
was prepared to 0.747 mM in Milli-Q purified sterile
 . water Millipore; Bedford, MA corresponding to 1
.mgrml . For all experiments, the indicated amounts
of lipid and DNA were complexed for 20–25 min at
room temperature in Opti-MEM medium without
 .serum GIBCO . During lipidrDNA complex forma-
tion, cells were washed twice with 1 ml Opti-MEM
medium, and 0.2 or 0.3 ml of Opti-MEM medium
was placed on each well. The lipidrDNA mixture
was then added gently in a volume of 0.2 ml per
well. The transfection solution remained on the cells
for 4 h at 378C in a 5% CO incubator and was then2
replaced with 2 ml of DME-HG medium. Cells were
further incubated for indicated periods of time before
the luciferase or Alamar Blue assays and p24 deter-
mination. Cells treated with either cationic lipids,
DNA or medium alone served as controls. Treatment
with DNA alone was not toxic in any of the experi-
ments reported in this study. Treatment with the
lipids alone served as a control for the cytotoxic
effect of the transfection procedure.
Transfection efficiency was measured by b-gal
staining. Briefly, transfected cells were washed with
PBS, fixed in the fixative solution containing 2%
formaldehyde and 0.2% glutaraldehyde, and stained
with an X-gal containing solution. The cells were
checked under a phase contrast microscope for the
development of blue color.
2.5. HIV infection of transfected HeLa CD4q cells
The virus and infected cells were handled in a
BL-3 facility. Twenty-four hours after transfection,
HeLa CD4q cells were exposed to HIV-1 for 2 hIIIB
at 378C, washed twice to remove unbound virus and
 .cultured in RPMI medium 2 ml per well . Control
cells were treated similarly but not exposed to virus.
The infection was monitored by determining viral
p24 in culture supernatants by an antigen capture
w x ELISA assay 30 , using a Molecular Devices Menlo
.Park, CA V microplate reader.max
2.6. Cell ˝iability assay
Cell morphology was evaluated by inverted phase
contrast microscopy at 25= magnification. The num-
ber of viable cells used for experiments was deter-
mined by Trypan Blue exclusion. Cell viability after
transfection was quantified by a modified Alamar
w x  .Blue assay 34 . Briefly, 1.0 ml of 10% vrv Alamar
Blue dye in the appropriate medium was added to
each well. After incubation for various times de-
.scribed under figure legends at 378C, 200 ml of the
supernatant was collected from each well and trans-
ferred to 96-well plates. The absorbance at 570 nm
and 600 nm was measured with a microplate reader.
Cell viability as a percentage of mock-treated con-
.trol cells was calculated according to the formula
 .  .A yA of test cells=100r A yA of570 600 570 600
control cells. After removal of the Alamar
Bluermedium mixture, fresh growth medium was
added, and cells were returned to the incubator. Thus,
the Alamar Blue assay allows determination of viabil-
ity over the culture period without the detachment of
adherent cells. A good correlation was obtained be-
tween the Alamar Blue assay and Trypan Blue stain-
w xing 35 .
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2.7. Luciferase assay
Luciferase activity was assayed using a kit ob-
 .tained from Promega Madison, WI and a scintilla-
tion counter 1209 RACKBETA, Pharmacia LKB
.Nuclear, Gaithersburg, MD according to the manu-
facturer’s instructions to increase sensitivity. A stan-
dard curve of cpm vs. enzyme concentration was
produced using purified luciferase.
3. Results
3.1. Trans-acti˝ation of the HIV-regulated luciferase
gene in HeLarLAV cells
In preliminary experiments the transfection activity
of LFA, Lipofectin or DMRIE was optimized by
using different amounts of the HIV-regulated lu-
w xciferase gene, pLUCA43 5 . Chronically infected
HeLarLAV cells were transfected with 0.5, 1 or 2
mg of the plasmid DNA complexed with 5 ml of
LFA, Lipofectin or DMRIE. These lipid concentra-
tions correspond to 6.25 mM LFA, 8.5 mM Lipo-
fectin and 9.4 mM DMRIE. Luciferase activity was
measured after 1 and 2 days. The highest level of
expression was observed with 2 mg pLUCA43 com-
  .plexed with LFA a lipid:DNA wrw ratio of 5:1
 . .and a charge ratio qry of 6.25 . A substantial
level of expression was also observed with 2 mg
  .pLUCA43 and DMRIE a lipid:DNA wrw ratio of
 . .2.5:1 and a charge ratio qry of 0.8 . Transfec-
tion with Lipofectin resulted in low expression of
luciferase. In further experiments 2 mg plasmid DNA
was complexed with 5 ml LFA or 8 ml DMRIE a
 .lipid:DNA wrw ratio of 4:1 and a charge ratio
 . .qry of 1.0 .
We first examined whether the HIV-regulated lu-
ciferase gene could be expressed in an HIV-depen-
dent manner following transfection by cationic lipo-
somes. The plasmids pLUCA43 containing Tatq
.Rev-responsive luciferase and pRSVLUC were
transfected into uninfected or chronically infected
HeLa cells. The HIV-regulated luciferase gene was
expressed at a 103-fold higher level in chronically
infected HeLarLAV cells compared to uninfected
HeLa cells, while the level of expression of RSV-reg-
ulated luciferase was the same in both cell lines Fig.
Fig. 1. HIV-regulated but not RSV-regulated luciferase gene
expression was increased in chronically infected HeLarLAV
cells. HeLa and HeLarLAV cells were transfected with 2 mg
pLUCA43 or pRSVLUC complexed with 6.25 mM LFA 5
.  .mlr400 ml Opti-MEM medium , at a lipid:DNA wrw ratio of
  . .  .5:1 charge ratio qry s6.25 , as described in Section 2. A
Cells were lysed 2 days post-transfection and luciferase activity
was expressed as cpm. Data represent the mean"standard devia-
 .tion obtained from duplicate wells. B Cell viability was mea-
sured 2 days post-transfection, by incubation with Alamar Blue
for 2 h at 378C, and was expressed as percent of the control. Data
represent the mean"standard deviation obtained from duplicate
wells from one experiment and are representative of three sepa-
rate experiments.
.1A . Transfection with either plasmid reduced cell
viability by about 40%, while treatment with LFA
alone reduced the viability of HeLa and HeLarLAV
 .cells by 30% and 20%, respectively Fig. 1B .
3.2. Inhibition of p24 production by the HIV-regu-
lated DT-A gene after co-transfection with an HIV
pro˝iral plasmid
To demonstrate that the HIV-regulated DT-A gene
could be expressed in cells that also express the HIV
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genome, following transfection by cationic lipo-
somes, the plasmid HXBDBgl was employed in a
transient assay. If the DT-A gene is expressed and an
active DT-A is produced, then it is expected that
transfected cells are substantially impaired in their
ability to produce HIV due to the high cellular lethal-
ity of DT-A. HeLa cells were transfected with the
HIV proviral clone, HXBDBgl, together with the
 .HIV-regulated DT-A plasmid pTHA43 complexed
with DMRIE. The DT-A frameshift mutant plasmid
 .pTHA44 and the pRSVLUC plasmid were used as
controls. HIV-1 expression and replication, as mea-
sured by p24 production on days 2 and 4, was
completely inhibited in cells co-transfected with
HXBDBgl and pTHA43 plasmids. The amounts of
p24 antigen determined in the culture supernatants of
HeLa cells co-transfected with HXBDBgl and
 .pTHA44 or pRSVLUC were similar Table 1 . Co-
transfection with HXBDBgl and any of the three
plasmids as well as treatment with DMRIE alone
reduced cell viability by about 20–30% on day 4
 .post-transfection data not shown . The results indi-
cated that HeLa cells could efficiently express HIV-
regulated DT-A after transfection with cationic lipo-
somes. The subpopulation of cells transfected with
HXBDBgl and pTHA43 did not produce any de-
tectable viral p24, while cells transfected with
HXBDBgl together with either of the control plas-
mids, pTHA44 or pRSVLUC, produced significant
amounts of p24.
3.3. Deli˝ery of HIV-DT-A to cells chronically in-
fected with HIV
If the HIV-regulated DT-A gene can be expressed
following transfection by cationic liposomes and is
upregulated in infected cells by HIV-encoded Tat and
Rev regulatory proteins, we hypothesized that HIV-
infected cells may be targeted for destruction by
DT-A. Chronically infected HeLarLAV cells and
uninfected HeLa cells were transfected with the
 .HIV-regulated DT-A plasmid pTHA43 , the DT-A
 .frameshift mutant plasmid pTHA44 or pRSVLUC
TM  .plasmid complexed with LipofectAMINE LFA .
Transfection with any of the three plasmids inhibited
virus production in HeLarLAV cell culture super-
 .natants by ;50% Fig. 2A and reduced cell viabil-
ity by ;30–40%. Treatment with LFA alone re-
duced the viability of HeLarLAV cells by ;15%
 .Fig. 2B . Thus, the observed inhibition of viral
production could be attributed primarily to non-
specific toxicity. Under the same experimental condi-
tions, the viability of uninfected HeLa cells was
reduced by ;30%, after transfection with any of the
three plasmids. The viability was reduced by 20%
 .following treatment with LFA alone data not shown .
Inhibition of p24 production was also observed
when HeLarLAV cells were transfected with
pTHA43, pTHA44 or pRSVLUC plasmids com-
plexed with DMRIE, although the overall toxicity
was lower by approximately 20% compared to that of
Table 1
 . ap24 production ngrml in HeLa cells co-transfected with HXBDBgl and pTHA43, pTHA44 or pRSVLUC plasmids
 .  .Plasmids Quantity of DNA mg p24 ngrml
Day 2 Day 4
HXBDBglqpTHA43 0.5r0.5 0 0
1.0r1.0 0 0
HXBDBglqpTHA44 0.5r0.5 0.25"0.10 1.34"0.15
1.0r1.0 0.57"0.07 3.62"0.42
HXBDBglqpRSVLUC 0.5r0.5 0.17"0.03 0.75"0.17
1.0r1.0 0.70"0.12 3.50"0.23
a  .p24 production ngrml is shown on days 2 and 4 following co-transfection of HeLa cells with either 0.5 mg or 1.0 mg each of
 .HXBDBgl and pTHA43, pTHA44 or pRSVLUC plasmids complexed with DMRIErDOPE 8 mlr500 ml of Opti-MEM medium , at a
 .  .lipid:DNA wrw ratio of 8:1 or 4:1. The charge ratio qry for the 8:1 and 4:1 complex was 2.0 and 1.0, respectively. Day 1 was
omitted because all samples were negative for p24 antigen. The transfection procedure was performed as described in Section 2. Data
represent the mean " standard deviation obtained from triplicate wells. Results are from one experiment and are representative of two
separate experiments.
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Fig. 2. Transient transfection of HeLarLAV cells with HIV-DT-A
did not have a specific effect on virus production. HeLarLAV
cells were transfected with 2 mg of pTHA43, pTHA44 or
pRSVLUC complexed with 6.25 mM LFA 5 mlr400 ml Opti-
.  . MEM medium , at a lipid:DNA wrw ratio of 5:1 the charge
 . .  .ratio qry s6.25 , as described in Section 2. A The produc-
tion of p24 antigen within a 24 h period was determined in
culture supernatants on days 1, 2 and 3 post-transfection and was
expressed as percent of control 100%: 68.8"3.6, 162.5"11.7
.and 203.8"16.9 ng p24rml on days 1, 2 and 3, respectively .
Data represent the mean"standard deviation obtained from tripli-
 .  .cate wells ns6 . B Cell viability was measured on days 1, 2
and 3 post-transfection incubation with Alamar Blue for 1 h 30
.min at 378C , and was expressed as percent of the control. Data
represent the mean"SD obtained from triplicate wells. Results
are from one experiment and are representative of three separate
experiments.
LFA. Under the same experimental conditions, trans-
fection of uninfected HeLa cells with any of the three
plasmids complexed with DMRIE was not cytotoxic.
In addition, DMRIE alone had no detectable toxic
effects on either HeLarLAV or HeLa cells data not
.shown .
One likely explanation for the lack of inhibition of
p24 production in HeLarLAV cells by pTHA43
plasmid is that the efficiency of transfection was too
low to affect significantly the level of p24 antigen in
culture supernatants of cells normally producing high
quantities of virus. Even if HIV-regulated DT-A ex-
pression could cause the death of a small portion of
Fig. 3. Transient transfection of HeLarIIIB cells with HIV-DT-A
did not have a specific effect on virus production. HeLarIIIB
cells were transfected with 2 mg of pTHA43 or pTHA44 com-
 .plexed with 12 mM DMRIE 8 mlr500ml Opti-MEM medium ,
 .   .at a lipid:DNA wrw ratio of 4:1 the charge ratio qry s
.  .1.0 , as described in Section 2. A p24 production within a 24 h
period was determined in culture supernatants on days 2 and 3
post-transfection, and was expressed as percent of control 100%:
1.2"0.1 and 1.74"0.16 ng p24rml on days 2 and 3, respec-
.tively . Data represent the mean"standard deviation obtained
 .  .from duplicate wells ns4 . B Cell viability was measured on
days 2 and 3 post-transfection incubation with Alamar Blue for
.2 h at 378C , and was expressed as percent of the control. Data
represent the mean"standard deviation obtained from duplicate
wells. Values shown are from one experiment.
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Fig. 4. Virus production after de novo infection of HeLa CD4q
cells transfected with HIV-DT-A. HeLa CD4q cells were trans-
fected with 1 or 2 mg of pTHA43 or pTHA44 complexed with 12
 .mM DMRIE 8 mlr500ml Opti-MEM medium , at a lipid:DNA
 .   . . wrw ratio of 8:1 the charge ratio qry s2.0 or 4:1 the
 . .charge ratio " s1.0 . The cells were infected 24 h later with
HIV-1 at 5=103 TCID per well, as described in Section 2.IIIB 50
One and 2 days post-infection, the culture medium was replaced
with fresh medium, and 5 days post-infection the culture super-
natants were analyzed for viral p24. The p24 antigen production
within the previous 72 h period was expressed as percent of the
 .control 100%: 0.21"0.05 ng p24rml . Cell viability was mea-
sured on day 5 post-infection incubation with Alamar Blue for 2
.h 40 min at 378C and was expressed as percent of the control.
Data represent the mean"SD obtained from duplicate wells or
quadruplicate control wells. Values shown are from one experi-
ment and are representative of two separate experiments.
HeLarLAV cells, without causing non-specific toxic-
ity, the high level of virus production by cells not
expressing the DT-A gene did not allow for the
detection of any reduction in p24 levels. We therefore
examined the effect of transfection on virus produc-
tion by a cell line producing much lower levels of
virus.
HeLarIIIB cells developed in our laboratory after
infection of HeLa CD4q cells with HIV-1 , pro-IIIB
duce 50 to 100-fold lower levels of p24 antigen than
HeLarLAV cells. Transfection of HeLarIIIB cells
with the pTHA43 plasmid complexed with DMRIE
did not reduce viral p24 production in a specific
manner. The production of p24 antigen in the culture
supernatant was inhibited by ;50% and 60% after
transfection with pTHA43 and pTHA44 plasmids,
 .respectively Fig. 3A . Transfection with either plas-
mid reduced the viability of HeLarIIIB cells by
;60%, while treatment with DMRIE alone reduced
 .viability by ;20% Fig. 3B .
3.4. Transfection of HIV-DT-A into HeLa CD4q
cells before infection
In contrast to data shown in Table 1, the data
 .presented above Figs. 2 and 3 show that expression
of pTHA43, delivered using cationic liposomes, did
not specifically reduce p24 production in chronically
infected HeLa cells. Therefore, we next examined if
p24 production could be reduced during de novo
infection of previously transfected cells. HeLa CD4q
cells were transfected with pTHA43 or pTHA44 plas-
 .mid complexed with DMRIE as before , and on the
next day the cells were infected with HIV-1 . TheIIIB
production of p24 antigen was inhibited by ;40%
and 60% after transfection with either of the two
 .plasmids, at 1 mg or 2 mg, respectively Fig. 4 .
Transfection with either plasmid or treatment with
DMRIE alone reduced the viability of infected HeLa
q  .CD4 cells by ;40% Fig. 4 .
Table 2
p24 production, luciferase activity, and b-gal activity in HeLa cells co-transfected with HXBDBgl and pCMV.SPORT-bgal or
pRSVLUC plasmids, and pCMV.SPORT-bgal and pRSVLUC plasmids a
HXBDBglqpCMV.SPORT-bgal HXBDBglqpRSVLUC pCMV.SPORT-bgalqpRSVLUC
 .p24 ngrml 0.25"0.01 0.29"0.04 0
4 4 .Luciferase cpm 0 6.8=10 "1.9=10 ND
 .b-gal positive cells % 3.6 0 6.5
a p24 production, luciferase activity and transfection efficiency are shown 2 days after co-transfection of HeLa cells with 1.0 mg each of
HXBDBgl and pCMV.SPORT-bgal or pRSVLUC plasmids, or pCMV.SPORT-bgal and pRSVLUC plasmids, complexed with 12 mM
 .  .   . .DMRIErDOPE 8 mlr500 ml of Opti-MEM medium , at a lipid:DNA wrw ratio of 4:1 charge ratio qry s1.0 . The
transfection procedure was performed as described in Section 2. Data represent the mean " standard deviation obtained from duplicate
wells. Values shown are from one experiment and are representative of two separate experiments. ND: not determined.
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3.5. Efficiency of transfection
HeLa cells were co-transfected with the HIV
proviral clone, HXB DBgl, together with the
pCMV.SPORT-bgal plasmid or the pRSVLUC plas-
mid complexed with DMRIE. As a control for co-ex-
pression of b-galactosidase, the pCMV.SPORT-bgal
plasmid was also co-transfected with the pRSVLUC
plasmid. HIV-1 expression and replication as mea-
.sured by p24 production , luciferase activity and the
efficiency of transfection were determined after 2
days. The amounts of p24 antigen determined in the
culture supernatants of HeLa cells co-transfected with
HXBDBgl and pCMV.SPORT-bgal or pRSVLUC
 .were similar Table 2 . The efficiency of transfection
was determined by scoring the percentage of cells
positive for b-galactosidase staining. Co-transfection
with pCMV.SPORT-b gal and HXB DBgl or
pRSVLUC, yielded 3.6% or 6.5% of cells expressing
 .b-gal, respectively Table 2 . Additional experiments
utilizing pCMV.SPORT-bgal and other control plas-
mids also indicated that the efficiency of transfection
 .was similarly low data not shown .
4. Discussion
In this study, we investigated whether HIV-regu-
lated luciferase and DT-A genes are expressed in
HIV-infected or HIV-expressing HeLa cells follow-
ing transfection by cationic liposomes, and whether
transient expression of the DT-A gene could affect
p24 production in chronically or acutely infected
 .HeLa cells. Our results demonstrate that i expres-
sion of the HIV-regulated luciferase gene is specifi-
 .cally trans-activated in HeLarLAV cells; ii co-
transfection of HeLa cells with HIV-DT-A and the
HIV proviral clone completely inhibits virus produc-
 .tion; iii expression of HIV-DT-A in chronically
infected HeLarLAV or HeLarIIIB cell cultures does
 .not specifically reduce p24 production; iv transient
expression of HIV-DT-A in HeLa CD4q cell cultures
 .does not protect against de novo HIV infection; v
transfection by cationic liposomes reduces the viabil-
 .ity of the cell culture; vi the observed reductions in
p24 levels can be ascribed primarily to non-specific
 .toxicity due to the transfection procedure; and vii
 .  .the results in iii and iv can be explained by the
low efficiency of lipofection in HeLa cells.
The introduction of a gene encoding a lethal prod-
uct, e.g. DT-A, linked with regulatory elements that
respond specifically to viral trans-activating proteins,
could mediate the killing of HIV-infected cells at an
early stage in the viral infectious cycle. For a highly
toxic molecule such as DT-A, expression must be
restricted to HIV-infected cells, as even low-level
expression of the toxin in uninfected cells would be
detrimental. Since cationic liposomes appear to be a
relatively safe and non-immunogenic alternative to
virus-mediated gene delivery for gene therapy in vivo
w x18–22 , we examined whether cationic liposomes
could be used to deliver HIV-DT-A into HIV-in-
fected cells. In contrast to retroviral or adeno-associ-
 .ated virus AAV -based gene deliveries, liposome-
 .mediated transfection like other non-viral systems is
expected to result in a short transient expression of
the heterologous gene due to the episomal nature of
w xthe transfected plasmid 36 . However, even low
transient expression of an inducible suicide DT-A
gene in an HIV-infected cell would be expected to
result in cell death.
HeLa cells were selected in our study because they
are relatively easy to transfect and are frequently
used in studies of transient and stable transfections.
Moreover, chronically HIV-infected HeLa cells are
available, and HeLa cells expressing the CD4
molecule are infectable with HIV. In addition, HeLa
cell clones stably expressing HIV- DT-A sequences
produce less HIV, by p24 assay, than parental HeLa
cells, after transfection with an HIV proviral clone
w xusing electroporation 6 . In our initial experiments
we attempted to determine the level of luciferase
expression under HIV control in HIV-infected mono-
cytic and T lymphocytic cell lines. The level of
expression in these cell lines was very low, and in
some cases, difficult to reproduce.
Whether actual HIV infection could activate HIV-
regulated luciferase has not been demonstrated previ-
ously. The expression of luciferase from the HIV-reg-
 .ulated luciferase gene pLUCA43 was induced by
the HIV proviral clone, HXBDBgl, in HeLa cells
transiently co-transfected by electroporation with
w xpLUCA43 and HXBDBgl 6 . DT-A expression from
 .the HIV-DT-A pTHA43 plasmid was assayed indi-
rectly in transiently or stably transfected HeLa cells
w x5,6 . HeLa cells were transiently co-transfected by
electroporation with pRSVLUC, and pTHA43 with or
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without pH3tatqpH3art plasmids expression plas-
.mids for Tat and Rev, respectively . In the presence
of both Tat- and Rev-encoding plasmids, the expres-
sion of luciferase was inhibited by 70%. The authors
suggested that trans-activation of DT-A expression
from pTHA43 by TatqRev results in inhibition of
 . w xluciferase presumably at the translational level 5 .
The decreased expression of a luciferase reporter
gene was also observed in HeLa cell clones contain-
ing integrated HIV-DT-A sequences after co-transfec-
tion by electroporation with pRSVLUC and Tat- and
w xRev-encoding plasmids 6 .
Since liposomes are approved for clinical trials
w x23 , we examined the potential of using this delivery
system for eventual gene therapy in vivo. In this
study we wanted to establish whether the HIV-regu-
 .lated luciferase gene pLUCA43 or HIV-DT-A could
be activated by an actual HIV infection, e.g. in
chronically HIV-infected cells. We demonstrated for
 .the first time that i the HIV-regulated luciferase was
expressed at a significantly higher level in HIV-in-
 .fected cells than in uninfected HeLa cells, and ii
HIV-DT-A genes were expressed specifically in
HIV-expressing HeLa cells following lipofection.
The first question raised by our results is why
expression of HIV-DT-A did not confer protection
against HIV infection. In order to be transcribed,
transfected genes must be delivered into the cell, and
ultimately to the nucleus in functional form. Our
results indicate that, although transfection with
cationic liposomes results in expression of HIV-regu-
lated genes in HeLa cells, the percentage of trans-
fected cells is too low to inhibit virus production in
HIV-infected cells or to protect against de novo HIV
infection. The low expression can be explained by the
inefficient entry of the lipid-DNA complex into the
cell, inefficient entry of the DNA into the nucleus or
degradation of the DNA.
 .The precise mechanism s by which lipid-DNA
complexes interact with the cell membrane are un-
known. It has been suggested that the majority of
DNA complexed to cationic liposomes is taken up
through endocytosis, followed by its release from an
early endosomal compartment possibly mediated by
the destabilization of the endosome membrane by the
. w xcationic lipids and DOPE 37–40 . Since fusion of
the endocytotic vesicles with lysosomes would lead
to degradation of the DNA, the DNA must enter the
cytoplasm before this fusion event for successful
w xtransfection to occur. Recently, Xu and Szoka 41
have suggested that the endocytosed lipid-DNA com-
plex destabilizes the endosomal membrane and in-
duces flip-flop of anionic lipids located predomi-
nantly on the cytoplasmic face of the membrane. The
diffusion of these lipids into the lipid-DNA complex
was proposed to result in the displacement of the
DNA from the complex and release of the DNA into
the cytoplasm. It has also been proposed that lipo-
some-mediated transfection involves translocation of
DNA through pores across the membranes rather than
w xdelivery via fusion or endocytosis 42 . Our previous
studies have shown that DOTMA liposomes can fuse
w xwith T lymphocytic cells 43 . More recent studies
indicate that DOTAP liposomes and their complexes
with DNA can undergo extensive fusion with the
plasma membrane of monocytic cells P. Pires, S.
Simoes, N. Duzgunes¸ and M.C. Pedroso de Lima,˜ ¨ ¨
.unpublished data . Very little is known about the
mechanism by which DNA is transferred into the
nucleus, except that only a small percentage of the
cytoplasmically delivered DNA reaches the nucleo-
w xplasm 44–46 . Therefore, further studies are needed
 .to understand the mechanism s by which DNA com-
plexed to cationic liposomes is delivered into the
nucleus and how these events are related to the
efficiency of transfection.
The low efficiency of transfection obtained in our
study suggests that additional methods need to be
employed for the efficient delivery of the DT-A gene
to HIV-infected cells, either by significantly improv-
ing transfection procedures, e.g. by using transferrin-
w xcationic liposome complexes 47 , or by appropriately
altering the transfection vectors. It has been shown
recently that high efficiency of lipofection and long-
term expression of heterologous genes can be
achieved by using plasmids containing the inverted
 . w xterminal repeats ITRs from AAV 48,49 . The au-
thors of these studies speculate that the presence of
the ITRs facilitates the nuclear accumulation of the
transfected plasmid. Episomal self-replicating plas-
mids contain a viral origin of DNA replication and a
virally encoded early gene that trans-activates the
viral DNA origin of replication, allowing for episo-
w xmal replication in the transfected host cell 50 . It has
been shown recently, using a liposome delivery sys-
tem, that a construct containing an episomal DNA
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vector of the human papovavirus BKV and a lu-
ciferase reporter gene yields widespread and long-
w xlasting expression of luciferase in mice 51 . The use
of some of these altered vectors may enhance the
efficacy of HIV-DT-A gene expression and may con-
fer protection against HIV infection. Targeting
cationic liposome-DNA complexes to HIV-infected
cells by covalently coupling anti-gp120 or anti-gp41
w xantibodies or soluble CD4 52 to liposomes may be
an alternative strategy to enhance gene delivery and
expression. The possible immunogenicity of such
w xtargeting constructs 53,54 may be a complicating
factor in their use in vivo. Nevertheless, strategies to
reduce the immunogenicity of targeting ligands, such
as the use of human monoclonal Fab fragments or
w xsynthetic peptides 55 may be developed. In a differ-
ent targeting strategy, efficient transfer of the
pCMV-luciferase gene to HepG2 hepatoma cells was
obtained with lipopolyamine-condensed DNA parti-
cles presenting galactose ligands that recognize the
w xasialoglycoprotein receptor on these cells 56 .
The next question raised by our findings is the
relatively high toxicity of the lipofection procedure to
HeLa cells. In our study, uninfected CD4y or CD4q
HeLa cells and infected HeLarLAV or HeLarIIIB
cells were exposed to lipid-DNA complexes, or lipids
alone, in Opti-MEM medium without serum, for 4 h
 .at 378C. Our results demonstrate that i cells differ in
their sensitivity to the toxic effect of cationic lipo-
 .somes, ii the formation of complexes between
cationic liposomes and DNA increases the toxic ef-
 .fect of liposomes, and iii in HeLarLAV cells, virus
production is more sensitive to the toxic effects of
liposome-DNA complexes or liposomes alone than is
the overall viability of the cells as measured by a
metabolic assay.
Both cationic liposomes alone and liposome-DNA
complexes show various levels of growth inhibition
and toxicity to cells in vitro, depending on the cell
type and the confluency of the cell culture
w x15,26,35,57–62 . The molecular and cellular basis of
this variability is not known. In contrast to the high
toxicity observed in vitro, very low toxicity was
reported following administration of various lipo-
w xsome-DNA complexes to animals 63–67 .
Nevertheless, a proper comparison of toxicities in
vitro and in vivo would have to involve the use of
much higher concentrations of serum or plasma in
cell culture experiments. These conditions, however,
are likely to inhibit the transfection activity and
efficiency of liposome-DNA complexes. It is also
likely that the interaction of the complexes with
plasma components in vivo inhibits their toxic ef-
fects. It is interesting to note that under the same
conditions cationic liposomes alone, either LFA or
DMRIE, are less toxic than their complexes with
DNA. These results confirm our previous observa-
w xtions 35 that the concentration of net positive charge
per se is not a determinant of toxicity. Cytotoxicity is
more likely to be associated with the structure of the
cationic molecules and their complexes with DNA,
their interactions with the cell membrane and their
ability to be metabolized by the cell.
Although our studies have focused on HIV-con-
trolled DT-A expression, we are aware of the poten-
tial limitations of toxin gene therapy in vivo. Never-
theless, the efficient and stable delivery of this gene
therapy system by lipofection can be translated read-
ily to other therapeutic strategies, such as those utiliz-
w xing anti-HIV ribozyme genes 68–70 .
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